Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03622593 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 951
- Enrollment target
NCT03622593 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 951 participants.
The verdict
NCT03622593, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 951 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Interventions
- PROCEDURE Sham Procedure
- DRUG Faricimab
- DRUG Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 951 participants |
| Start Date | 2018-10-09 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03622593
The ClinicalTrials.gov registry entry for NCT03622593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 951 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT03622593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03622593 about?
NCT03622593 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema". This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
What is the current status of trial NCT03622593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 951 participants. The study started on 2018-10-09. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT03622593?
The interventions under investigation include: Sham Procedure (PROCEDURE), Faricimab (DRUG), Aflibercept (DRUG).
Who is sponsoring clinical trial NCT03622593?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.